Immunization with short peptide particles reveals a functional CD8⁺ T-cell neoepitope in a murine renal carcinoma model.

ABSTRACT:

Background

Induction of CD8⁺ T cells that recognize immunogenic, mutated protein fragments in the context of major histocompatibility class I (MHC-I) is a pressing challenge for cancer vaccine development.

Methods

Using the commonly used murine renal adenocarcinoma RENCA cancer model, MHC-I restricted neoepitopes are predicted following next-generation sequencing. Candidate neoepitopes are screened in mice using a potent cancer vaccine adjuvant system that converts short peptides into immunogenic nanoparticles. An identified functional neoepitope vaccine is then tested in various therapeutic experimental tumor settings.

Results

Conversion of 20 short MHC-I restricted neoepitope candidates into immunogenic nanoparticles results in antitumor responses with mu

SUBMITTER: He X 

PROVIDER: S-EPMC8647534 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature